What Kafra Treats: Main Uses and Benefits

Kafra (Ofloxacin) is a therapeutic agent applied in contexts where additional symptomatic support is needed for infections caused by susceptible bacteria. Its core purpose is to provide an antimicrobial effect, which is commonly used to help with the management of bacterial infections and supports the easing of related symptoms.

The medication is considered relevant across therapeutic domains involving infections of the genitourinary tract (such as complicated UTIs and chronic prostatitis), the lower respiratory system (specific pneumonias), and targeted localized infections (including bacterial conjunctivitis and otitis media/externa). These uses help address symptom clusters that may become intense or disruptive, such as fever, painful urination, localized redness, and discharge.

Applied when appropriate, Kafra supports the management of conditions characterized by periods of heightened symptoms and contributes to improved day-to-day comfort.

---

Quick Fact: Relief for Inflammatory Discomfort The medication is relevant for easing symptoms related to inflammatory or irritative states, particularly in the eyes and ears, helping to support functional stability during acute episodes.

Regulatory References

1. NIH StatPearls overview of Ofloxacin's approved uses

Kafra (Ofloxacin) eligibility is strictly defined by regulatory authorities and is generally restricted to adults who do not possess specific risk factors or contraindications. Systemic use is absolutely contraindicated in several populations.

Who Cannot Use Kafra (Contraindications)

Category	Restriction
Age	Systemic use is contraindicated in children and growing adolescents (typically under 18 years) due to the risk of joint cartilage damage.
Allergy	Patients with known hypersensitivity to Ofloxacin, other fluoroquinolone antibacterials, or any excipient.
Comorbidity	Patients with a history of epilepsy or certain CNS disorders, myasthenia gravis, or tendon disorders related to previous fluoroquinolone use.
Reproductive Status	Contraindicated for use in pregnant and breastfeeding women.

---

Conditional Eligibility (Requires Caution)

Eligibility is conditional for certain groups due to how the body processes the medicine or pre-existing risks:

• Renal Impairment: Patients with impaired renal function (e.g., creatinine clearance le 50 mL/min) are eligible only if a dosage adjustment is performed.
• Cardiovascular/Aortic Risk: Use is generally avoided in patients with a history of or risk factors for aortic aneurysm or known QTc interval prolongation.
• Special Risk Factors: Caution is required for older adults (ge 60 years) and those taking corticosteroid drugs due to an increased risk of tendon rupture.

Kafra Interactions with other medicines and products

Official regulatory information describes specific interaction patterns for Kafra (Ofloxacin), primarily involving reduced absorption, affected clearance, and additive effects on certain physiological functions.

---

Documented Interaction Categories

Category	Interacting Products / Agents
Absorption Restriction (Chelation)	Antacids, Sucralfate, Iron salts, Zinc preparations, Didanosine (chewable/buffered tablets)
Pharmacodynamic Reinforcement	Non-steroidal Anti-inflammatory Drugs (NSAIDs), Theophylline, QT-prolonging agents (e.g., Class IA and III antiarrhythmics, tricyclic antidepressants, macrolides)
Altered Clearance / Exposure	Probenecid, Cimetidine, Furosemide, Methotrexate, Warfarin, Glibenclamide

---

Official Regulatory Statements

• Timing Separation Required: The co-administration of Kafra with multivalent cation-containing products (such as aluminum- or magnesium-containing antacids, iron, or zinc supplements) significantly reduces Ofloxacin absorption. These agents must not be taken within the two-hour period before or after Kafra administration.
• Exposure Modification: Co-administration with drugs that compete for renal tubular excretion (e.g., Probenecid) can decrease Kafra's clearance, potentially increasing its systemic exposure. Conversely, Kafra can increase the plasma concentrations of certain co-administered drugs like Glibenclamide or Procainamide.
• Additive Risk: Concurrent use with NSAIDs may lower the cerebral seizure threshold. The use of Kafra with other drugs known to prolong the QT interval carries an additive risk of cardiac effects.
• Population Notes: Close monitoring of coagulation parameters (PT/INR) is required when Kafra is combined with Vitamin K antagonists (e.g., Warfarin). Close monitoring of blood glucose is needed in diabetic patients receiving Glibenclamide.

Targeted Disruption of Bacterial DNA Enzymes

The mechanism of Kafra begins with the selective inhibition of two critical bacterial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. By binding to and blocking the function of these topoisomerases, Ofloxacin halts the essential processes of DNA supercoiling, unwinding, and the final segregation of the bacterial chromosome. This action constitutes an interference with the pathogen's essential genetic machinery.

The Bactericidal Cascade: Inducing Irreparable DNA Damage

The enzyme inhibition leads to a lethal molecular cascade: Ofloxacin stabilizes the DNA-enzyme complex in a state where the bacterial DNA is cleaved but cannot be repaired. This results in the rapid, unavoidable accumulation of double-strand DNA breaks throughout the chromosome. This extensive, non-reversible genetic damage triggers the cell's destruction, achieving a bactericidal (bacteria-killing) physiological effect that eliminates the susceptible microbial cells.

Mechanistic Specificity and Limits

The mechanism relies on selective toxicity, targeting bacterial enzyme structures that are distinct from those in human cells, which results in the mechanism primarily affecting the pathogen's enzyme structure. However, the mechanism is constrained by bacterial mutations in the target enzymes or the activation of efflux pumps that actively expel Ofloxacin, physiological processes that can functionally reduce the drug’s destructive mechanism.

How to Use Kafra (Ofloxacin) Based on Official Prescribing Instructions

Kafra (Ofloxacin) must be used strictly according to the official instructions provided, which define the correct route, dose, frequency, and duration of therapy.

---

Approved Administration Routes and Forms

Ofloxacin is approved for several administration routes, enabling treatment for both systemic and localized infections:

• Oral: Taken as tablets (200 mg, 300 mg, 400 mg) for systemic use.
• Intravenous (IV) Infusion: Used when oral administration is not feasible, providing comparable systemic exposure to oral dosing (mg/mg).
• Topical: Applied as specialized aqueous solutions (0.3%) for localized treatment of the eyes (ophthalmic) and ears (otic).

---

Standard Dosing and Frequency

For most systemic infections, the standard adult regimen is a dose of 200 mg to 400 mg, taken twice daily (every 12 hours). The total daily dose typically ranges from 400 mg to a maximum of 800 mg. For certain uncomplicated infections, a single 400 mg dose may be prescribed. If the daily dose exceeds 400 mg, it must be divided into two separate, equally-spaced doses.

Administration Detail	Official Instruction Summary
With or Without Food	Oral tablets may be taken with or without food.
Administration Timing	Oral tablets should be swallowed whole; avoid taking within two hours of antacids or mineral supplements.
IV Infusion	Must be administered slowly; for example, a 400 mg dose is typically infused over 60 minutes.

---

Course Duration and Adjustments

Treatment duration varies widely, ranging from short courses (e.g., 3 days for some uncomplicated urinary tract infections) up to 6 weeks for conditions like prostatitis. Patients must complete the full prescribed course.

Dose Adjustment for Renal Function: A reduction in dose and/or frequency is required for patients with impaired kidney function (Creatinine Clearance le 50 mL/min), often leading to a once-daily maintenance dose.

Research Evidence: Overview of Studies for Kafra (Ofloxacin)

The clinical research for Kafra (Ofloxacin) was evaluated in specific infectious conditions, and patterns observed in the studies contribute to the broader evidence landscape. The evidence primarily comes from Randomized Controlled Trials (RCTs), where Ofloxacin was compared to a placebo or other antimicrobial agents, and from systematic reviews and meta-analyses.

---

Evidence for Systemic Infections: Urinary and Respiratory Tracts

Research explored the use of Ofloxacin tablets for conditions associated with acute or disruptive episodes, specifically those of the urinary tract and lower respiratory system. The focus of these trials monitored outcomes related to systemic or functional imbalance, specifically bacteriological clearance and symptom change.

Trial Design and Measured Outcomes for Systemic Uses

For urinary tract infections (UTIs), studies examined patterns related to measured bacteriological clearance in controlled trial settings. However, some evidence suggests that certain shorter courses reported differing measured clearance when compared to multi-day regimens. For lower respiratory tract infections, research has explored short-term symptom changes and described measured outcomes against susceptible organisms in trials. Regulatory guidelines often mandate that Ofloxacin was reserved for use only when other commonly recommended antibiotics are inappropriate or unavailable for these conditions.

---

Evidence for Localized Infections: Topical Eye and Ear Applications

The evidence for the liquid (solution) forms of Ofloxacin was evaluated in localized infection sites, such as bacterial infections of the eye (ophthalmic) and ear (otic). This evidence includes high-level systematic reviews and meta-analyses.

For otic infections, studies monitored the resolution of ear discharge (otorrhea) and overall clinical success. Research highlights changes measured during the study period, with some findings indicated measured patterns over defined time intervals. Similarly, for ophthalmic infections, research explored outcomes related to microbiological clearance in subjects with conditions like bacterial conjunctivitis and corneal ulcers.

Key Studies & References

1. Ofloxacin - StatPearls (NIH Bookshelf)
2. Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate

Common questions about Kafra (FAQ)

Q: What should I do if I miss a dose of Ofloxacin?

If a dose of Kafra is missed, it is generally advised to take the missed dose as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped. Official regulatory instructions advise against taking a double dose to compensate for the one that was missed.

Q: Is Kafra (Ofloxacin) safe to use while breastfeeding?

Official prescribing information indicates that systemic use of Ofloxacin (tablets or IV infusion) is generally contraindicated for women who are breastfeeding. This is because Ofloxacin can pass into breast milk. In contrast, official sources note that topical forms like eye or ear drops typically result in very low systemic exposure and are considered to pose a negligible risk.

Q: Can Kafra (Ofloxacin) cause sun sensitivity?

Yes, regulatory warnings indicate that Ofloxacin, like other medicines in the fluoroquinolone class, can cause photosensitivity reactions. This means skin may become more sensitive to direct sunlight. Official guidance notes that avoiding unnecessary exposure to the sun or sunlamps may help reduce the risk of photosensitivity.

Q: Can Kafra (Ofloxacin) be crushed or cut for easier swallowing?

Official regulatory instructions for the oral tablets state that they should be swallowed whole. Official product information emphasizes that the tablets should be swallowed whole and does not specify alternative administration methods like crushing or cutting.

Q: Does Kafra interact with commonly used heart/blood pressure medications?

Official drug information specifically notes that Kafra can interact with certain heart medicines, particularly those known as Class IA and III antiarrhythmics. These interactions carry an additive risk of prolonging the QT interval, which may lead to serious heart rhythm changes. Therefore, co-administration typically requires careful management by a healthcare provider.

Q: How do I dispose of leftover or expired Ofloxacin?

Official environmental guidelines state that Kafra should not be disposed of via household trash or drains. Unused or expired medication and waste materials must be disposed of according to local pharmaceutical waste rules. This usually involves using an approved drug take-back or disposal program.

Q: How long should I take Ofloxacin for?

The required length of treatment varies widely based on the specific infection being treated. Official dosing tables indicate durations ranging from a few days (e.g., 3 days for some uncomplicated urinary tract infections) up to 6 weeks for conditions like prostatitis. Completing the full duration prescribed is typically advised by healthcare professionals.

Q: Are there any known foods or drinks I should avoid while on Kafra?

Official sources note that Ofloxacin should not be taken within two hours of products containing multivalent cations, such as antacids, iron supplements, or zinc supplements. This restriction is necessary because these products can significantly decrease the amount of Ofloxacin absorbed by the body.

The storage and disposal of Kafra (Ofloxacin) must strictly follow the conditions defined in official regulatory labeling to ensure product integrity and public safety.

Storage Requirements

Labeled Storage Temperature Requirements:	Must be stored at controlled room temperature, generally below 25 C or 30 C.
Light/Moisture Protection Requirements:	Must be protected from light and kept in a tightly closed container.
Packaging-Related Storage Rules:	Must be stored in the original container or packaging.
Child-Protection Storage Requirements:	Must be stored out of the sight and reach of children.

Disposal Instructions

Disposal Instructions (as documented in government sources):	Dispose of the unused product and any waste material according to local requirements.
Environmental Waste Requirements:	Should not be disposed of via wastewater or household waste; follow local environmental rules.

These official statements specify that the medicine requires environmental control, including temperature regulation and protection from light and moisture, to maintain its stability. Disposal must follow designated local pharmaceutical waste programs to prevent environmental contamination, as discarding the product via drains or ordinary household trash is prohibited.